A genome-wide meta-analysis identifies 53 sequence variants associating with carpal tunnel syndrome

Astros Skuladottir (✉ astros.skuladottir@decode.is)

deCODE Genetics (Iceland) <https://orcid.org/0000-0002-5048-0933>

Gyda Bjornsdottir

deCODE Genetics (Iceland) <https://orcid.org/0000-0002-8100-0306>

Egil Ferkingstad

deCODE Genetics (Iceland) <https://orcid.org/0000-0001-8090-7988>

Gudmundur Einarsson

deCODE Genetics/Amgen <https://orcid.org/0000-0002-1326-2339>

Lilja Stefansdottir

deCODE Genetics/Amgen

Muhammad Sulaman Nawaz

deCODE Genetics/Amgen <https://orcid.org/0000-0002-5576-9007>

Thorunn Olafsdottir

deCODE genetics/Amgen Inc., Reykjavik, Iceland. <https://orcid.org/0000-0001-5454-938X>

Saedis Saevarsdottir

deCODE genetics/Amgen Inc., Reykjavik, Iceland <https://orcid.org/0000-0001-9392-6184>

G. Walters

deCODE genetics/Amgen <https://orcid.org/0000-0002-5415-6487>

Sigurdur Magnusson

deCODE Genetics <https://orcid.org/0000-0001-6669-3071>

Asmundur Oddson

deCODE genetics

Anna Bjornsdottir

Laeknasetrid Clinic

Olafur Sveinsson

Landspítali, the National University Hospital of Iceland

Arnor Vikingsson

Landspítalinn, National University Hospital of Iceland, Reykjavik

Thomas Hansen

Copenhagen University Hospital <https://orcid.org/0000-0001-6703-7762>

Rikke Jacobsen

Copenhagen University Hospital

Christian Erikstrup

Aarhus University Hospital <https://orcid.org/0000-0001-6551-6647>

Michael Schwinn

Copenhagen University Hospital

Søren Brunak

University of Copenhagen <https://orcid.org/0000-0003-0316-5866>

Karina Banasik

University of Copenhagen <https://orcid.org/0000-0003-2489-2499>

Sisse Ostrowski

Department of Clinical Immunology, Rigshospitalet <https://orcid.org/0000-0001-5288-3851>

Anders Troelsen

Copenhagen University Hospital <https://orcid.org/0000-0003-0132-8182>

Cecilie Henkel

Copenhagen University Hospital Hvidovre <https://orcid.org/0000-0002-4219-5374>

Ole Pedersen

Næstved Sygehus <https://orcid.org/0000-0003-2312-5976>

Ingileif Jonsdottir

deCODE Genetics (Iceland) <https://orcid.org/0000-0001-8339-150X>

Daniel Gudbjartsson

deCODE Genetics (Iceland) <https://orcid.org/0000-0002-5222-9857>

Patrick Sulem

deCODE Genetics (Iceland) <https://orcid.org/0000-0001-7123-6123>

Thorgeir Thorgeirsson

deCODE Genetics/Amgen Inc.

Hreinn Stefansson

deCODE genetics/Amgen, Inc.

Kari Stefansson

deCODE genetics <https://orcid.org/0000-0003-1676-864X>

Article

Keywords:

Posted Date: January 14th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1189337/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Nature Communications on March 24th, 2022. See the published version at <https://doi.org/10.1038/s41467-022-29133-7>.

Abstract

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy and has a largely unknown underlying biology. In a genome-wide association study of CTS ($N_{\text{cases}} = 48,843$, $N_{\text{controls}} = 1,190,837$), we found 53 sequence variants at 50 loci that associate with the syndrome. The most significant association is with a missense variant (p.Glu366Lys) in *SERPINA1* that protects against CTS ($P = 2.9 \times 10^{-24}$, OR = 0.76). Through various functional analyses, we conclude that at least 22 genes mediate CTS risk and highlight the role of 19 CTS variants in the biology of the extracellular matrix. We show that the genetic component to the risk is higher in recurrent/persistent cases than nonrecurrent/nonresistant cases. Anthropometric traits including height and BMI are genetically correlated with CTS, in addition to early hormonal-replacement therapy, osteoarthritis, and restlessness. Our findings suggest that the components of the extracellular matrix play a key role in the pathogenesis of CTS.

Introduction

Entrapment neuropathies are common and debilitating. In these neuropathies, a peripheral nerve becomes compressed where it passes through narrow anatomical areas, due to swelling of surrounding tissues or anatomical abnormalities¹. Carpal tunnel syndrome (CTS) is the most common form of entrapment neuropathy, affecting around 3% of women and 2% of men at some stage in their lives². It is caused by elevated pressure on the median nerve in the carpal tunnel³, a space-limited osteofibrous canal that, in addition to the median nerve, contains the carpal bones, the transverse carpal ligament, and the flexor tendons⁴. The median nerve innervates muscles of the hand and CTS patients commonly experience severe pain and paresthesia, and less commonly weakness, in the median nerve distribution⁴.

Although CTS has been widely studied, its pathophysiology is not fully understood. A combination of factors such as mechanical trauma (e.g. wrist fractures), fibrosis, and inflammation of tendons can lead to pressure on the median nerve within the carpal tunnel⁵. Other risk factors include age, female sex², pregnancy⁶, obesity, diabetes, and heredity⁷.

The diagnosis of CTS is obtained through medical assessment such as Phalen's and Tinel's test, and/or electrophysiological measurement *i.e.* nerve conduction velocity across the carpal tunnel⁴. Several treatments are available for the management of CTS, ranging from lifestyle changes (e.g. reduction of certain work activities) to local corticosteroid injection, and in the most severe cases, surgical carpal tunnel decompression.

The estimated familial occurrence of CTS is 17-39%^{8,9} and the heritability of CTS has been estimated to be 0.46 in women¹⁰. The largest reported genome-wide association study (GWAS) of CTS yielded 16 risk loci using data from 12,312 cases and 389,344 controls from the UK¹¹. Here, we expand the previous study by combining 48,843 cases and 1,190,837 controls from Iceland (deCODE genetics), the UK (UK Biobank), Denmark (Danish Blood Donor Study [DBDS] and Copenhagen Hospital Biobank [CHB]), and Finland (Finngen) in a GWAS meta-analysis of CTS, and find 53 independent sequence variants at 50 loci, thereof 32 novel.

Results

GWAS meta-analysis

In a meta-analysis, we combined CTS GWAS results for 37.1 million sequence variants using 48,843 cases and 1,190,837 controls from Iceland, the UK, Denmark, and Finland (Table 1, Supplementary Table 1). We applied logistic regression to test for the association of sequence variants with CTS under an additive model, and combined the GWAS summary results of each dataset in a fixed-effects inverse variance model. To account for multiple testing, we used weighted genome-wide significance thresholds based on the predicted functional impacts of the associated variants¹² (Supplementary Table 2).

Table 1

Summary of the GWAS datasets in the CTS meta-analysis

Population	GWAS dataset	Sequence variants (M)	Cases (N)	Controls (N)
Iceland	deCODE genetics	20,697,529	8,122	318,161
The UK	UK Biobank	32,381,502	19,849	411,179
Denmark	Copenhagen Hospital Biobank	27,776,695	9,664	266,450
	The Danish Blood Donor Study			
Finland	Finngen	12,830,475	11,208	195,047
Total			48,843	1,190,837

Sequence variants at 50 loci associated with CTS (Figure 1, Table 2, and Supplementary Data 1). Conditional analyses revealed secondary signals at three of the loci (Table 2, Supplementary Fig. 1, and Supplementary Data 2).

Of the 53 variants, 32 represent novel associations with CTS while 21 have previously been associated with CTS^{11,13}, directly or through a correlated variant ($r^2 \geq 0.2$) at the corresponding locus in our results (Table 2, Supplementary Data 3). At six of the 21 reported loci, we found associating coding variants, an in-frame deletion, three splice region variants, and two missense variants, while all previously reported variants at these loci are non-coding (Supplementary Data 3). To test the 21 previously reported variants in our meta-analysis, we re-ran meta-analyses excluding the datasets that overlap with the discovery datasets. One of the variants was only present in the Finnish dataset (EAF = 0.10%) and thus could not be validated. Of the 20 remaining variants, we found support for 19 signals with the same direction of effect in the datasets tested ($P \leq 0.05$; Supplementary Data 3).

Table 2

Sequence variants associated with CTS. The *P*-value and odds ratios are shown for the combined analysis.

^aSecondary signal from the conditional analysis presented with adjusted *P*-value and OR. *EA* effect allele, *OA* other allele, *EAF* effect allele frequency, *CI* confidence interval.

rs name	Chr:Position (hg38)	EA/OA	EAF (%)	Annotation	Closest protein-coding gene	OR (95% CI)	<i>P</i> -value
rs28929474	chr14:94378610	T/C	1.86	Missense	<i>SERPINA1</i>	0.76 (0.72, 0.80)	2.9×10^{-24}
rs12694411	chr2:217281820	T/A	26.4	Intergenic	<i>DIRC3</i>	0.92 (0.91, 0.94)	3.3×10^{-24}
rs11205303	chr1:149934520	C/T	38.8	Missense	<i>MTMR11</i>	0.93 (0.92, 0.95)	7.0×10^{-21}
rs62621197	chr19:8605262	T/C	2.89	Missense	<i>ADAMTS10</i>	1.20 (1.16, 1.25)	7.2×10^{-20}
rs66525731	chr4:13221803	T/C	11.1	Intergenic	<i>RAB28</i>	1.10 (1.08, 1.12)	8.6×10^{-20}
rs72755233	chr15:100152748	A/G	12.1	Missense	<i>ADAMTS17</i>	1.10 (1.08, 1.12)	2.7×10^{-19}
rs3791679	chr2:55869757	G/A	21.8	Intron	<i>EFEMP1</i>	1.08 (1.06, 1.10)	4.1×10^{-19}
rs1474313	chr4:8327339	G/A	27.4	Intergenic	<i>HTRA3</i>	1.07 (1.05, 1.08)	3.6×10^{-18}
rs1325494	chr10:98186463	G/C	43.0	Splice region	<i>R3HCC1L</i>	0.94 (0.93, 0.95)	7.0×10^{-18}
rs9722048	chr9:133563561	A/G	44.0	Intron	<i>ADAMTSL2</i>	1.06 (1.05, 1.07)	1.8×10^{-16}
rs150512726	chr3:124763647	T/TTTGT TGAAC	11.3	Inframe deletion	<i>ITGB5</i>	0.92 (0.89, 0.93)	2.2×10^{-15}
rs9923544	chr16:53768073	T/C	43.1	Intron	<i>FTO</i>	1.06 (1.04, 1.07)	5.0×10^{-15}
rs2871960	chr3:141402972	C/A	46.2	Upstream	<i>ZBTB38</i>	0.95 (0.94, 0.96)	3.3×10^{-14}

rs name	Chr:Position (hg38)	EA/OA	EAF (%)	Annotation	Closest protein- coding gene	OR (95% CI)	P- value
rs2815536	chr10:27644947	A/G	42.2	Intergenic	<i>MKX</i>	0.95 (0.94, 0.96)	3.8 × 10 ⁻¹⁴
rs6977081	chr7:150845427	T/G	32.8	Regulatory region	<i>AOC1</i>	0.95 (0.93, 0.96)	4.0 × 10 ⁻¹⁴
rs79101546	chr9:126910488	T/G	26.1	Upstream	<i>RALGPS1</i>	0.94 (0.93, 0.96)	5.8 × 10 ⁻¹⁴
rs12762780	chr10:70672742	C/A	47.9	5' UTR	<i>ADAMTS14</i>	1.05 (1.04, 1.07)	6.2 × 10 ⁻¹⁴
rs7251031	chr19:11156017	G/T	29.0	Upstream	<i>SPC24</i>	1.06 (1.04, 1.08)	2.8 × 10 ⁻¹³
rs4655025	chr1:22133261	A/G	44.6	Intron	<i>WNT4</i>	0.95 (0.94, 0.96)	3.8 × 10 ⁻¹³
rs1866745	chr15:66742474	A/G	35.4	Intron	<i>SMAD6</i>	1.05 (1.04, 1.07)	4.7 × 10 ⁻¹³
rs10916207	chr1:227780237	G/A	49.6	Downstream	<i>SNAP47</i>	0.95 (0.94, 0.97)	6.4 × 10 ⁻¹³
rs2807360 ^a	chr1:22163678	C/G	33.5	Intergenic	<i>WNT4</i>	1.06 (1.04, 1.08)	7.8 × 10 ⁻¹³
rs17214004	chr7:84370484	T/C	10.4	Intergenic	<i>SEMA3A</i>	1.08 (1.06, 1.11)	1.5 × 10 ⁻¹²
rs6712473	chr2:33188573	G/T	46.3	Splice region	<i>LTBP1</i>	1.05 (1.04, 1.06)	1.6 × 10 ⁻¹²
rs72725608	chr14:75779563	C/T	4.12	Intron	<i>TTLL5</i>	1.13 (1.09, 1.16)	4.0 × 10 ⁻¹²
rs12539945	chr7:16082848	A/G	44.3	Downstream	<i>ISPD</i>	1.05 (1.03, 1.06)	4.9 × 10 ⁻¹²
rs5758007	chr22:40559560	T/A	48.8	Intron	<i>MKL1</i>	1.05 (1.03, 1.06)	6.4 × 10 ⁻¹²

rs name	Chr:Position (hg38)	EA/OA	EAF (%)	Annotation	Closest protein- coding gene	OR (95% CI)	P- value
rs1394094	chr3:136476946	A/T	31.1	Intron	<i>STAG1</i>	0.95 (0.94, 0.96)	6.6 × 10 ⁻¹²
rs6117726	chr20:7262893	T/C	47.9	Intergenic	<i>BMP2</i>	0.95 (0.94, 0.97)	9.0 × 10 ⁻¹²
rs41314549	chr1:155320440	C/T	2.20	Missense	<i>FDPS</i>	1.16 (1.11, 1.22)	7.8 × 10 ⁻¹¹
rs1008384	chr7:44139027	G/A	25.2	Splice region	<i>MYL7</i>	0.95 (0.93, 0.96)	1.2 × 10 ⁻¹⁰
rs73978133	chr2:176004276	T/C	20.3	Upstream	<i>LNPK</i>	0.95 (0.93, 0.96)	1.5 × 10 ⁻¹⁰
rs11598539	chr10:129043829	C/T	24.4	Intergenic	<i>MGMT</i>	0.95 (0.94, 0.97)	1.7 × 10 ⁻¹⁰
rs2581348 ^a	chr15:99973858	C/T	32.7	3' UTR	<i>ADAMTS17</i>	1.05 (1.03, 1.07)	2.1 × 10 ⁻¹⁰
rs10043462	chr5:98430152	A/G	47.3	Intergenic	<i>RGMB</i>	0.96 (0.95, 0.97)	2.4 × 10 ⁻¹⁰
rs57822625	chr10:30817960	T/C	13.2	Intergenic	<i>ZNF438</i>	1.07 (1.04, 1.08)	2.5 × 10 ⁻¹⁰
rs56214011	chr6:85098630	A/G	7.74	Intergenic	<i>TBX18</i>	0.92 (0.90, 0.94)	2.7 × 10 ⁻¹⁰
rs147467236	chr6:33181796	AT/A	16.7	Downstream	<i>COL11A2</i>	0.94 (0.92, 0.96)	2.8 × 10 ⁻¹⁰
rs12459350 ^a	chr19:2176587	G/A	46.3	Intron	<i>DOT1L</i>	0.95 (0.93, 0.97)	3.9 × 10 ⁻¹⁰
rs17328524	chr2:59934022	C/T	40.4	Intergenic	<i>BCL11A</i>	0.96 (0.95, 0.97)	3.9 × 10 ⁻¹⁰
rs7119588	chr11:66609564	C/T	5.14	Downstream	<i>CCS</i>	1.10 (1.07, 1.13)	4.2 × 10 ⁻¹⁰

rs name	Chr:Position (hg38)	EA/OA	EAF (%)	Annotation	Closest protein-coding gene	OR (95% CI)	P-value
rs1048661	chr15:73927205	T/G	33.2	Missense	<i>LOXL1</i>	0.96 (0.94, 0.97)	7.6×10^{-10}
rs61749613	chr5:83519351	G/A	3.91	Missense/splice	<i>VCAN</i>	1.11 (1.08, 1.15)	8.5×10^{-10}
rs604168	chr12:69277378	G/A	28.9	Downstream	<i>CPSF6</i>	1.05 (1.03, 1.06)	1.1×10^{-9}
rs41277466	chr22:41825842	T/C	9.30	3' UTR	<i>CCDC134</i>	0.93 (0.91, 0.95)	1.1×10^{-9}
rs12050196	chr14:99673097	C/T	44.0	Downstream	<i>HHIPL1</i>	0.96 (0.94, 0.97)	1.3×10^{-9}
rs3753841	chr1:102914362	G/A	38.6	Missense	<i>COL11A1</i>	0.96 (0.94, 0.97)	2.0×10^{-9}
rs2287002	chr19:2038820	A/G	23.1	3' UTR	<i>MKNK2</i>	0.95 (0.94, 0.97)	2.1×10^{-9}
rs1064583	chr6:116125413	G/A	38.8	Missense	<i>COL10A1</i>	0.96 (0.95, 0.97)	3.3×10^{-9}
rs1075653	chr3:52791512	C/T	37.3	Splice region	<i>ITIH1</i>	1.04 (1.03, 1.06)	3.6×10^{-9}
rs2286323	chr2:241097382	G/A	10.0	Start lost	<i>MTERF4</i>	0.93 (0.91, 0.95)	1.4×10^{-8}
rs67245807	chr10:5007406	G/C	20.6	Splice donor	<i>AKR1C2</i>	1.05 (1.03, 1.07)	4.4×10^{-8}
rs2736911	chr10:122454839	T/C	15.5	Stop gained	<i>ARMS2</i>	0.95 (0.93, 0.97)	1.1×10^{-7}

The effect estimates of the 53 CTS variants identified in the meta-analysis were in the same direction in all four datasets (Supplementary Fig. 3) and there was no evidence of heterogeneity (all $P_{\text{het}} \geq 0.05/53 = 9.4 \times 10^{-4}$). The UK dataset was largest and 10 of the 53 variants reached the genome-wide significance in that dataset. Of the 53 variants, 5 are low-frequency variants (EAF < 5%), including the missense variant (p.Glu366Lys) in *SERPINA1*, which has the largest effect on CTS ($P = 2.9 \times 10^{-24}$, OR = 0.76). We constructed a polygenic risk score (PRS) based on effect estimates from the meta-analysis, excluding the UK dataset, and predicted into the

UK dataset. The PRS explained 2% of the variance. SNP heritability estimated using linkage disequilibrium (LD) score regression¹⁴, was 0.19 (95% CI 0.11-0.27) in Iceland, 0.34 (95% CI 0.30-0.38) in the UK, and 0.16 (95% CI 0.11-0.20) in Denmark.

Functional annotation

To search for causal genes associating with CTS at each locus (*i.e.* mediating the effect of variant on CTS), we annotated the 53 CTS sequence variants and correlated variants ($r^2 \geq 0.8$ and within +/- 1MB). Of these, 35 were predicted to affect coding or splicing of a protein ($N = 17$, Supplementary Data 4), mRNA expression (top cis expression quantitative trait loci [*cis*-eQTL]; $N = 24$, Supplementary Data 5), and/or plasma protein levels¹⁵ (top protein quantitative trait loci [*cis* and *trans*-pQTL]; $N = 10$, Supplementary Data 6). Of the 35 CTS variants and correlated variants, 22 had evidence that pointed to a single gene (Figure 2a and Supplementary Data 4-6). To estimate the deleteriousness of the 54 variants, we used a scaled Combined Annotation Dependent Depletion (CADD) score¹⁶, which ranks variants based on predicted pathogenicity, and found that 19 variants are among the top 10% of pathogenic variants, thereof 10 in the top 1% (Figure 2a and Supplementary Data 7). In addition, we performed a gene-set enrichment analysis in FUMA¹⁷ based on the genes at the 50 loci and found a strong enrichment for extracellular matrix components ($P_{\text{adj}} = 4.1 \times 10^{-11}$; Figure 2b and Supplementary Data 8).

CTS variant effect in ulnar and radial nerve lesions

Although not passing through the carpal tunnel, the ulnar and radial nerves course through the forearm and wrist to help co-ordinate the movement of the forearms and hands. Using data from Iceland, the UK, Denmark, and Finland, we performed meta-analyses of lesions of the ulnar nerve (9429 cases and 1,136,861 controls) and the radial nerve (1645 cases and 1,232,006 controls) to study the effect of the 53 CTS variants in these phenotypes. None of the variants associated with lesions of the ulnar or the radial nerve (Supplementary Data 9 and 10).

Polygenic risk score and sex effect

The most common causes of recurrent or persistent CTS include incomplete surgical release of the transverse carpal ligament, fibrous proliferation, and recurrent tenosynovitis. We constructed a CTS PRS using LDpred¹⁹ to estimate whether the level of genetic propensity varies in differently defined groups of CTS cases based on suggested clinical severity. We constructed the PRS for individual datasets (except the Finnish dataset for which we did not have individual level data) using summary data from the meta-analysis, leaving each dataset out in turn. Using the CTS PRS, we estimated the effect size in five groups defined as 1) all CTS cases ($N = 37,635$), 2) non-recurrent/non-persistent CTS cases ($N = 28,200$), 3) recurrent/persistent CTS cases ($N = 9,435$), 4) CTS cases that have undergone surgery ($N = 18,281$), and 5) CTS cases that experienced symptoms after surgery ($N = 2,843$). The recurrent cases were defined as cases with six or more months between healthcare encounters resulting in a CTS diagnosis and the recurrence rate was 25.1% (Iceland = 21.6%, the UK = 26.2%, and Denmark = 27.7%; Supplementary Table 1). As expected, recurrent CTS cases had higher PRS than nonrecurrent cases ($P_{\text{het}} = 1.5 \times 10^{-22}$; Figure 3 and Supplementary Figure 4). We did not observe a significant difference between CTS surgery and CTS symptoms after surgery.

CTS is more commonly reported among females than males and studies have shown that the carpal tunnel cross-sectional area relative to the size of the hand is smaller in females²¹. In the CTS study sample, 34% were males and 66% females (Supplementary Table 1) and the average age of diagnosis was 57 years for males and 55 years for females. Further, the recurrence was 25.4% in males and 27.1% in females. In light of reported sex differences in risk of CTS, we applied sex-specific models for the Icelandic, the UK, and Danish datasets for the 53 CTS variants (Supplementary Data 11), but no variant had an effect that significantly differed between the sexes after accounting for multiple testing ($P \geq 0.05/53 = 9.4 \times 10^{-4}$).

Low-frequency variant in *SERPINA1*

The variant with the largest effect on CTS risk was a low-frequency missense variant (p.Glu366Lys) in *SERPINA1*, present in all four datasets (rs28929474-T, EAF = 1.86%, OR = 0.76, $P = 2.9 \times 10^{-24}$). *SERPINA1* encodes α -1 antitrypsin and rs28929474-T has been reported to cause α -1 antitrypsin deficiency²². It has also been widely reported in the literature to associate with a broad range of traits^{23–27} (Bjornsdottir et al, in review), including multiple plasma proteins. Our results show that the variant affects 36 plasma proteins (Supplementary Data 6). The only variant in high LD ($r^2 \geq 0.8$) with rs28929474 is a downstream variant, rs112635299-T (Figure 4).

Genetic correlation and Mendelian randomization

We performed genetic correlation analyses using the CTS meta-analysis and summary statistics from 1319 GWASs ($P \leq 0.05/1319 = 3.8 \times 10^{-5}$, Supplementary Data 12)²⁸. We excluded the UK dataset from the meta-analysis as it overlaps with the data used in most of the summary statistics. Substantial genetic correlations have previously been reported between CTS and anthropometric traits including height and BMI¹¹. Our collective data of genetic correlation (Supplementary Data 12) and Mendelian randomization (MR; Supplementary Figure 5 and Supplementary Table 3), using 3290 variants previously associated with height²⁹ and 941 variants previously associated with BMI as instrumental variables, further support these findings. However, in contrast to the previous study, our results show evidence of confounding by unbalanced genetic pleiotropy for both height (intercept = -0.003, $P = 1.1 \times 10^{-11}$) and BMI (intercept = 0.006, $P = 2.2 \times 10^{-16}$). Of the genes reported in the CTS meta-analysis, 22 have previously been associated with height and 12 with body fat distribution (Supplementary Data 8). BMI is commonly used as a proxy measurement of body adiposity. However, BMI does not discriminate between adipose and lean mass, and between fat stored in different compartments of the body. Impedance measurements address this problem to some extent. CTS correlates genetically with both fat percentage and fat-free mass of arms, legs, and trunk based on LD score regression (Supplementary Data 12). Besides anthropometric traits, the strongest genetic correlation is between CTS and age when hormone-replacement therapy was started ($r_g = -0.48$, $P = 1.4 \times 10^{-12}$), other and unspecified osteoarthritis defined by ICD-10 code M19, which includes primary osteoarthritis of the wrists ($r_g = 0.68$, $P = 5.7 \times 10^{-11}$), and feeling restless ($r_g = 0.55$, $P = 5.4 \times 10^{-10}$).

Discussion

Here, we report a GWAS meta-analysis of CTS that combines 48,843 cases from four populations and expands previous studies by identifying 53 variants at 50 loci. Among these 53 variants is a low-frequency variant in

SERPINA1 that protects against CTS. Through fine-mapping, eQTL, pQTL, CADD score, and gene-set enrichment analysis, we highlighted potential effect-mediating genes and the biological roles of a large portion of the variants. Using PRS, we estimated the genetic propensity in differently defined severity groups of CTS and showed that recurrent CTS cases had higher PRS than nonrecurrent cases. There was a strong genetic correlation between CTS and early hormonal-replacement therapy, osteoarthritis, and feeling restless. Further, genetic correlation studies of anthropometric traits were consistent with previous findings but MR analyses showed evidence of genetic pleiotropy when using height and BMI variants as instrumental variables.

Based on functional annotation, we highlighted 35 genes that may participate in the pathogenesis of CTS. Three of the candidate causal genes are *COL11A1*, *COL11A2*, and *COL10A1*. These genes are members of the collagen family (COL) and encode collagens, the most abundant proteins in the extracellular matrix where they give structural support to resident cells and account for 90% of bone matrix protein content³⁰. *COL11A1* has previously been implicated in CTS³¹ and *COL11A1* and *COL11A2* have been implicated in tendinopathies^{32–34}. Mutations and abnormal expression of *COL10A1* have been linked to abnormal chondrocyte hypertrophy and osteoarthritis in humans^{35–37}, and *Col10a1* knockout mice have a reduced thickness of growth plate and articular cartilage, altered bone content, and atypical distribution of matrix components within growth plate cartilage³⁸. In our study, a variant in high LD ($r^2 = 0.98$) with the CTS variant in *COL10A1*, associates with Collagen α -1(X) chain in plasma ($P = 4.0 \times 10^{-180}$, $\beta = -0.25$; Supplementary Data 6), suggesting a decrease of the protein in CTS cases.

Collagens are substrates for disintegrin and metalloproteases with thrombospondin motifs (ADAMTS)³⁹ and members of the lysyl oxidase (LOX) family⁴⁰. Three of the candidate causal genes highlighted in the study encode ADAMTS (*ADAMTS10*, *ADAMTS14*, and *ADAMTS17*) and one encodes ADAMTS-like protein (*ADAMTSL2*), which resembles ADAMTS in structure but lacks proteolytic activity. ADAMTS have regulatory roles and are involved in the processing of procollagens to mature collagens and control the structure and function of the extracellular matrix⁴¹. Another collagen substrate and a highlighted gene, *LOXL1*, provides collagen fibers their tensile strength and structural integrity by oxidizing lysine residues, resulting in the covalent cross-linking and stabilization of these structural components⁴⁰. The missense variant (p.Arg141Leu) in *LOXL1* is among the top 1% of pathogenic variants (CADD score = 24.4). As ADAMTS process the COL substrates which are stabilized by LOX, we assume that these processes are inter-linked and speculate that distortion of one may affect the others and thus, increase the risk of CTS.

Other components of the extracellular matrix that were highlighted in the study include *SERPINA1* and *ITGB5*. The missense variant (p.Glu366Lys) in *SERPINA1* is the top signal in the meta-analysis and has a strong protective effect on CTS and also associates with the plasma levels of multiple proteins (Supplementary Data 6) supporting previously reported observations. *ITGB5* encodes a subunit of integrin which participates in cell adhesion in the extracellular matrix, and is upregulated in CTS cases⁴². The in-frame deletion reported here associates with plasma levels of several proteins (Supplementary Data 6) that are involved in collagen processes and immune response among other functions.

Using CTS PRS, we found differences between nonrecurrent/nonpersistent and recurrent/persistent CTS cases, indicating higher genetic propensity for CTS among recurrent cases. We did not have data on which hand was

affected and could not define bilateral CTS cases specifically. Thus, we were not able to exclude the possibility of CTS in each hand at different timepoints in a case defined as recurrent.

Entrapment neuropathies of the median, ulnar, and radial nerves are characterized by alteration of nerve function that are caused by mechanical or dynamic compression¹. None of the variants associating with CTS showed strong evidence of association with lesions of the ulnar or radial nerve, suggesting a specific pathology in CTS cases.

CTS is a common and debilitating. Our study identified genome-wide associations with CTS and revealed sequence variants that point to genes that may contribute to the pathogenesis. Our results suggest that the components of the extracellular matrix play a key role in the pathogenesis of CTS by putting pressure on the median nerve at the carpal tunnel.

Methods

Study sample and ethics statement

A large fraction of the Icelandic population has participated in a nationwide research program at deCODE genetics. Participants donated blood or buccal samples after signing a broad informed consent allowing the use of their samples and data in all projects at deCODE genetics approved by the National Bioethics Committee (NBC). The data in this study was approved by the NBC (VSN-19-158; VSNb2019090003/03.01) following review by the Icelandic Data Protection Authority. All personal identifiers of the participants' data were encrypted in accordance with the regulations of the Icelandic Data Protection Authority. The Icelandic CTS cases were obtained in collaboration with Icelandic physicians at Landspítali – National University Hospital in Reykjavik, the Registry of Primary Health Care Contacts, and the Registry of Contacts with Medical Specialists in Private Practice. The CTS cases were identified using International Classification of Diseases 10 (ICD-10) code G56.0, ICD-9 code 354.0, and Nomsec Classification of Surgical Procedures (NCSP) code ACC51 (decompression and freeing of nervus medianus) through the scrutiny of hospital records from 1985 to 2020. The cases with lesions of the ulnar and radial nerves were identified using ICD-10 code G56.2 and G56.3, respectively.

The UK Biobank resource includes extensive phenotype and genotype data from ~500,000 participants in the age range of 40 to 69 from across the UK that have provided an informed consent⁴³. The North West Research Ethics Committee reviewed and approved UK Biobank's scientific protocol and operational procedures (REC Reference Number: 06/MRE08/65). This study was conducted using the UK Biobank resource under application number 24898. CTS cases were identified by searching for ICD-10 code G56.0 and Classification of Interventions and Procedures (OPCS) codes A651 (carpal tunnel release) and A692 (revision of carpal tunnel release) in General Practice clinical event records (Field ID 42040) and UK hospital diagnoses (Field ID 41270 and 41271).

The Copenhagen Hospital Biobank (CHB) is a research biobank, which contains left over samples from diagnostic procedures on hospitalized and outpatients in the Danish Capital Region hospitals. Under the "Genetics of pain and degenerative diseases" protocol, approved by the Danish Data Protection Agency (P-2019-51) and the National Committee on Health Research Ethics (NVK-18038012), we identified CTS cases by ICD-10 code G56.0 and NCSP code ACC51 to identify CTS cases. The Danish Blood Donor Study (DBDS)

Genomic Cohort is a nationwide study of ~110,000 blood donors⁴⁴. The Danish Data Protection Agency (P-2019-99) and the National Committee on Health Research Ethics (NVK-1700407) approved the studies under which genetic data on DBDS participants were obtained. The DBDS data requested for this study was approved by the DBDS steering committee.

The FinnGen database consists of samples collected from the Finnish biobanks and phenotype data collected at the national health registers. The Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District evaluated and approved the FinnGen research project. The project complies with existing legislation (in particular the Biobank Law and the Personal Data Act). The official data controller of the study is the University of Helsinki. Subjects were identified using ICD-10 code G56.0 and ICD-9 code 354.0. NCSP-FI codes (Finnish NCSP adaption) was not available. The summary statistics for CTS were imported on May 11th, 2021 from a source available to consortium partners (version 5; <http://r5.finnngen.fi>).

Genetic ancestry quality control was performed for the Icelandic⁴⁵, British⁴⁶, and Danish⁴⁷ participants. All participants were genotypically verified as being of European descent.

In total, we had 48,843 carpal tunnel cases (8,122 from Iceland, 19,849 from the UK, 9,664 from Denmark, and 11,208 from Finland) and 1,190,837 controls (318,161 from Iceland, 411,179 from the UK, 266,450 from Denmark, and 195,047 from Finland) in the meta-analysis.

Genotyping and imputation

The preparation of the Icelandic samples, genotyping, whole-genome sequencing (WGS), and imputation was performed at deCODE genetics^{45,48}. The genomes of 49,962 Icelanders were WGS using GAllx, HiSeq, HiSeqX, and NovaSeq Illumina technology to a mean depth of at least 17.8×. Single nucleotide polymorphisms (SNPs) and insertions/deletions (indels) were identified and their genotypes called using joint calling with GraphTyper⁴⁹. Additionally, over 166,000 Icelanders (including all sequenced Icelanders) have been genotyped using various Illumina SNP chips and their genotypes phased using long-range phasing⁵⁰, which allows for improving genotype calls using haplotype sharing information. Subsequently, genealogic information was used to impute sequence variants into the chip-typed Icelanders, as well as their first- and second-degree relatives⁵¹ to increase the sample size and power for association analysis.

The UK Biobank samples were genotyped with a custom-made Affymetrix chip, UK BiLEVE Axiom in the first 50,000 individuals⁵², and the Affymetrix UK Biobank Axiom array⁵³ in the remaining participants. Samples were filtered on 98% variant yield and any duplicates removed. Over 32 million high-quality sequence variants and indels to a mean depth of at least 20× were identified using GraphTyper⁴⁹. Quality-controlled chip genotype data were phased using Shapeit4⁵⁴. Variants where at least 50% of the samples had a GQ score > 0 were used to prepare a haplotype reference panel using in-house tools and the long-range phased chip data. The haplotype reference panel variants were then imputed into the chip genotyped samples using in-house tools and methods described above for the Icelandic data^{45,50}.

Samples from 276,114 Danes from the CHB and DBDS were genotyped using Illumina Global Screening Array chips and long-range phased together with ~238,000 genotyped samples from North-western Europe using

Eagle2⁵⁵. Samples and variants with less than 98% yield were excluded. A haplotype reference panel was prepared in the same manner as for the Icelandic and UK data^{45,50} by phasing whole-genome sequence genotypes of 15,576 individuals from Scandinavia, the Netherlands, and Ireland using the phased chip data. GraphTyper was used to call the genotypes which were subsequently imputed into the phased chip data. Whole genome sequencing, chip-typing, quality control, long-range phasing, and imputation from which the data for this analysis were generated was performed at deCODE genetics.

A custom-made FinnGen ThermoFisher Axiom array (>650,000 SNPs) was used to genotype ~177,000 FinnGen samples at Thermo Fisher genotyping service facility in San Diego. Genotype calls were made with AxiomGT1 algorithm. Individuals with ambiguous gender, high genotype missingness (>5%), excess heterozygosity (± 4 SD), and non-Finnish ancestry were excluded. Variants with high missingness (>2%), low Hardy-Weinberg equilibrium ($< 1 \times 10^{-6}$), and minor allele count (<3) were excluded. High coverage (25-30 $\times$) WGS data was used to develop the Finnish population-specific SISu v3 imputation reference panel with Beagle 4.1. More than 16 million variants have been imputed (<https://finngen.gitbook.io/documentation/methods/genotype-imputation>).

Association analysis

We applied logistic regression using the Icelandic, UK, and Danish data and combined the results with imported association results from Finland (<https://r5.finngen.fi/>) to test for association between sequence variants and CTS. For the additive model, the expected allele counts were used as a covariate. We used LD score regression to account for distribution inflation due to cryptic relatedness and population stratification¹⁴ and used the intercepts as correction factors (CF) in the Icelandic (CF = 1.19), UK (CF = 1.03), and Danish (CF = 1.03) datasets.

In the Icelandic association analysis, we adjusted for sex, county of origin, age at data analysis or age at death (first and second order terms included), blood sample availability for the individual, and an indicator function for the overlap of the lifetime of the individual with the time span of phenotype collection. In the UK association analysis, we adjusted for sex, age, and the first 20 principal components⁴⁶. In the Danish association analysis, we adjusted for sex, whether the individual had been chip-typed and/or sequenced, and the first 20 principal components. The imported Finnish association analysis was adjusted for sex, age, the genotyping batch, and the first 10 principal components.

We combined CTS GWASs from Iceland, the UK, and Denmark with summary statistics from Finland using a fixed-effects inverse variance method⁵⁶ based on effect estimates and standard errors in which each dataset was assumed to have a common OR but allowed to have different population frequencies for alleles and genotypes. The total number of variants included in the meta-analysis that had imputation information above 0.8 and MAF > 0.01% was 37,071,338 (20,697,529 in Iceland, 32,381,502 in the UK, 27,776,695 in Denmark, and 12,830,475 in Finland). We estimated the genome-wide significance threshold using a weighted Bonferroni adjustment that controls for the family-wise error rate¹². Sequence variants were mapped to NCBI Build38 and matched on position and alleles to harmonize the four datasets. Variants were weighted based on predicted functional impact¹² (Supplementary Table 2).

Conditional association analyses were performed on the GWASs from Iceland, the UK, and Denmark using true imputed genotypes of participants. Approximate conditional analyses (COJO), implemented in the GCTA-software⁵³, were applied on the lead variants in the Finnish summary statistics. The analyses were restricted to variants within 1 Mb from the index variants. LD between variants was estimated using a set of 5,000 WGS Icelanders. After adjusting for all variants in high LD ($r^2 > 0.8$) and vice versa, the P -values were combined for all four datasets to identify the most likely causal variant at each locus and any secondary signals. Based on the number of variants tested, we chose a conservative P -value threshold of $< 5 \times 10^{-8}$ for secondary signals.

Polygenic risk score and heritability

Polygenic risk score (PRS) was generated using a set of 611,000 high quality variants across the genome were used to avoid uncertainty due to imputation quality⁵⁷. LD estimated from almost 15,000 phased Icelandic samples, was used derive adjusted effect estimates by applying LDpred¹⁹. The effect estimates were used as weights. We generated PRS into the Icelandic, the UK, and Danish datasets and used leave-one-out meta-analyses, where the summary data from that particular dataset was omitted, to avoid any bias in PRS estimates. In addition, we meta-analyzed the results from the dataset-specific PRS analyses using a random-effects model, fitted via maximum likelihood estimation²⁰. The unit of the effect for each PRS is in SD. Since the effects on CTS were comparable (overlapping confidence intervals), we performed no further scaling.

We estimated the SNP heritability for the combined CTS GWASs from Iceland, the UK, and Denmark using LD score regression¹⁴ and precomputed LD scores based on about 1.1 million variants from European ancestry samples (downloaded from: https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2).

Genetic correlation

Genetic correlation analyses between the CTS meta-analysis and 1,319 published GWAS traits ($P \leq 3.8 \times 10^{-5}$) from the UK Biobank²⁸ with effective sample size over 5,000 were performed using LD score regression^{14,58}, which suggests the minimal effective sample size of 5,000 for each trait to get unbiased estimates of genetic correlation and heritability. Since participants in the published GWAS studies are of Caucasian ancestry, we used pre-computed LD scores from a 1000 genome panel with r^2 from HapMap3, excluding HLA region. The HLA region was excluded for its genetic complexity and association with a wide number of traits. The default parameters of the LD score regression were used to compute the genetic correlation and heritability estimates.

Mendelian randomization

A two sample MR analysis was performed to estimate the causal relationship between CTS and exposure traits, that we used as instrumental variables. We used the inverse-variance-weighted (IVW) method to estimate the causal relationship between variables, a t-test to compute the P -value, and the Egger method to test for pleiotropy in IVW estimates, all implemented in the MendelianRandomization package⁵⁹ in R.

Functional data

To highlight potential causal genes associating with CTS, we annotated the CTS associations or variants in high LD ($r^2 \geq 0.8$ and within +/- 1MB) that are predicted to affect coding or splicing of a protein (variant effect predictor using Refseq gene set), mRNA expression (top local expression quantitative trait loci [*cis*-eQTL]) in multiple tissues from deCODE, GTEx (<https://www.gtexportal.org/home/>), and other public datasets, and/or plasma protein levels (top protein quantitative trait loci [pQTL]).

RNA sequencing was performed on whole blood from 13,175 Icelanders and on subcutaneous adipose tissue from 750 Icelanders, described in detail elsewhere⁶⁰. Gene expression was computed based on personalized transcript abundances using kallisto⁶¹. Association between sequence variants and gene expression (*cis*-eQTL) was estimated using a generalized linear regression, assuming additive genetic effect and quantile normalized gene expression estimates, adjusting for measurements of sequencing artefacts, demographic variables, blood composition, and hidden covariates⁶².

We used the SomaLogic® SOMAscan proteomics assay to test the association of the sequence variants with protein levels in plasma¹⁵. The assay scanned 4,907 aptamers that measure 4,719 proteins in samples from 35,559 Icelanders with genetic information available at deCODE genetics. Plasma protein levels were standardized and adjusted for year of birth, sex, and year of sample collection (2000-2019).

We performed gene-based enrichment analysis using the GENE2FUNC tool in FUMA. The genes were tested for over-representation in different gene sets, including Gene Ontology cellular components (MsigDB c5) and GWAS catalogue-reported genes.

Declarations

Data availability

The GWAS summary statistics for CTS are available at <https://www.decode.com/summarydata/>. Other data generated or analyzed in this study are included in the article and its Supplementary data and information.

Software availability

We used the following publicly available software to analyze the data:

GraphTyper (v2.0-beta, GNU GPLv3 license) at <https://github.com/DecodeGenetics/graph typer>.

Svimmer (v0.1, GNU GPLv3 license), the structural variant merging software at <https://github.com/DecodeGenetics/svimmer>.

SHAPEIT4 at <https://odelaneau.github.io/shapeit4/>.

Eagle2 at <http://www.hsph.harvard.edu/alkes-price/software/>.

GCTA (v1.93.3beta2) at <https://yanglab.westlake.edu.cn/software/gcta/#Overview>.

LDpred (v1.0.8) at <https://github.com/bvilhjal/ldpred>.

LD score regression at <https://github.com/bulik/ldsc>.

qqman package at <https://github.com/stephenturner/qqman>.

MandelianRandomization package at <https://github.com/cran/MendelianRandomization>.

metafor package at <https://wviechtb.github.io/metafor/>.

FUMA at <https://fuma.ctglab.nl/>.

We used version 3.6.3 of R and version 1.2.5042 of RStudio for statistical analyses and graphs and figures.

Acknowledgements

We thank the participants in this study for their valuable contribution to research. We thank all investigators and colleagues who contributed to data collection, phenotypic characterization of clinical samples, genotyping and analysis of the whole-genome association data. This research was conducted using the UK Biobank Resource (application number 24898). We acknowledge the participants and investigators of the FinnGen study. The financial support from the European Commission to the painFACT project (H2020-2020-848099) is acknowledged.

Author contributions

ATS, GB, HS, and KS designed the study. ATS, GB, EF, GE, LS, MSN, SHM, DFG, PS, TET, HS, and KS analyzed the data and interpreted the results. Data collection and subject ascertainment and recruitment was carried out by GB, GBW, AO, AB, OAS, AV, TFH, RLJ, CE, MS, SB, KB, SRO, AT, CH, OBP, DBDS GC, and IJ. ATS drafted the manuscript with input and comments from GB, EF, GE, LS, MSN, TAO, SS, GBW, AB, DFG, PS, TET, HS, and KS. All authors contributed to the final version of the manuscript.

Competing interests

ATS, GB, EF, GE, LS, MSN, TAO, SS, GBW, SHM, AO, IJ, DFG, PS, TET, HS, and KS are employees of deCODE genetics/Amgen Inc. The remaining authors declare no competing interests.

Corresponding authors

Correspondence to Astros Th. Skuladottir (astros.skuladottir@decode.is) or Kari Stefansson (kstefans@decode.is).

Danish Blood Donor Study (DBDS) Genetic Consortium

Steffen Andersen¹, Karina Banasik², Søren Brunak², Kristoffer Burgdorf³, Maria Didriksen³, Khoa Manh Dinh⁴, Christian Erikstrup⁴, Daniel F. Gudbjartsson^{5,6}, Thomas Folkmann Hansen^{2,7}, Henrik Hjalgrim⁸, Gregor Jemec⁹, Poul Jennum¹⁰, Pär Ingemar Johansson³, Margit Anita Hørup Larsen³, Susan Mikkelsen⁴, Kasper Rene Nielsen¹¹, Mette Nyegaard¹², Sisse Rye Ostrowski³, Ole Birger Pedersen¹⁴, Hreinn Stefánsson⁵, Susanne Sækmose¹⁴, Erik Sørensen³, Unnur Þorsteinsdóttir^{5,15}, Mie Topholm Bruun¹³, Henrik Ullum¹⁶, Thomas Werge¹⁷, Kari Stefansson^{5,15}

1. Department of Finance, Copenhagen Business School, Copenhagen, Denmark
2. Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3. Department of Clinical Immunology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
4. Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
5. deCODE Genetics/Amgen, Inc., Reykjavik, Iceland
6. School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland
7. Danish Headache Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet – Glostrup, Denmark
8. Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
9. Department of Clinical Medicine, Zealand University Hospital, Roskilde, Denmark
10. Department of Clinical Neurophysiology, University of Copenhagen, Copenhagen, Denmark
11. Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark
12. Department of Biomedicine, Aarhus University, Aarhus, Denmark
13. Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
14. Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
15. Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
16. Statens Serum Institute, Copenhagen, Denmark
17. Institute of Biological Psychiatry Mental Health Centre Sct. Hans Copenhagen University Hospital, Roskilde, Denmark

DBDS consortium contact is Ole B. Pedersen olbp@regionsjaelland.dk

References

1. England, J. D. Entrapment neuropathies. *Curr. Opin. Neurol.* **12**, 597–602 (1999).
2. Atroshi, I. *et al.* Prevalence of carpal tunnel syndrome in a general population. *J. Am. Med. Assoc.* **282**, 153–158 (1999).
3. Gelberman, R. H., Rydevik, B. L., Pess, G. M., Szabo, R. M. & Lundborg, G. Carpal Tunnel Syndrome: A Scientific Basis for Clinical Care. *Orthop. Clin. North Am.* **19**, 115–124 (1988).
4. Padua, L. *et al.* Carpal tunnel syndrome: clinical features, diagnosis, and management. *The Lancet Neurology* **15**, 1273–1284 (2016).

5. Rydevik, B., Lundborg, G. & Bagge, U. Effects of graded compression on intraneural blood flow: An in vivo study on rabbit tibial nerve. *J. Hand Surg. Am.* **6**, 3–12 (1981).
6. Oliveira, G. A. D., Bernardes, J. M., Santos, E. S. & Dias, A. Carpal tunnel syndrome during the third trimester of pregnancy: prevalence and risk factors. *Arch. Gynecol. Obstet.* **300**, 623–631 (2019).
7. Geoghegan, J. M., Clark, D. I., Bainbridge, L. C., Smith, C. & Hubbard, R. Risk factors in carpal tunnel syndrome. *J. Hand Surg. Am.* **29**, 315–320 (2004).
8. Radecki, P. The familial occurrence of carpal tunnel syndrome. *Muscle Nerve* **17**, 325–330 (1994).
9. Puchalski, P., Szlosser, Z. & Żyluk, A. Familial occurrence of carpal tunnel syndrome. *Neurol. Neurochir. Pol.* **53**, 43–46 (2019).
10. Hakim, A. J., Cherkas, L., El Zayat, S., MacGregor, A. J. & Spector, T. D. The genetic contribution to carpal tunnel syndrome in women: a twin study. *Arthritis Rheum.* **47**, 275–279 (2002).
11. Wiberg, A. *et al.* A genome-wide association analysis identifies 16 novel susceptibility loci for carpal tunnel syndrome. *Nat. Commun.* **10**, (2019).
12. Sveinbjornsson, G. *et al.* Weighting sequence variants based on their annotation increases power of whole-genome association studies. *Nat. Genet.* **48**, 314–317 (2016).
13. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes. *Nat. Genet.* **53**, 1415–1424 (2021).
14. Bulik-Sullivan, B. *et al.* LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
15. Ferkingstad, E. *et al.* Large-scale integration of the plasma proteome with genetics and disease. *Nat. Genet.* **53**, 1712–1721 (2021).
16. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* **46**, 310–315 (2014).
17. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1–11 (2017).
18. Amendola, L. M. *et al.* Actionable exomic incidental findings in 6503 participants: challenges of variant classification. *Genome Res.* **25**, 305 (2015).
19. Vilhjálmsson, B. J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. *Am. J. Hum. Genet.* **97**, 576–592 (2015).
20. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *J. Stat. Softw.* **36**, 1–48 (2010).
21. Sassi, S. A. & Giddins, G. Gender differences in carpal tunnel relative cross-sectional area: a possible causative factor in idiopathic carpal tunnel syndrome. *J. Hand Surg. Eur. Vol.* **41**, 638–642 (2016).
22. Zorzetto, M. *et al.* SERPINA1 Gene Variants in Individuals from the General Population with Reduced α 1-Antitrypsin Concentrations. *Clin. Chem.* **54**, 1331–1338 (2008).
23. Pazoki, R. *et al.* Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. *Nat. Commun.* **12**, 2579 (2021).
24. Kichaev, G. *et al.* Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *Am. J. Hum. Genet.* **104**, 65 (2019).

25. Emdin, C. A. *et al.* Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene–Environment Interaction Study. *Gastroenterology* **160**, 1620–1633.e13 (2021).
26. Ferkingstad, E. *et al.* Genome-wide association meta-analysis yields 20 loci associated with gallstone disease. *Nat. Commun.* **9**, 1–11 (2018).
27. Olafsson, S. *et al.* Common and Rare Sequence Variants Influencing Tumor Biomarkers in Blood. *Cancer Epidemiol. Biomarkers Prev.* **29**, 225–235 (2020).
28. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex traits. *Nat. Genet.* **51**, 1339–1348 (2019).
29. Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Hum. Mol. Genet.* **27**, 3641 (2018).
30. Tzaphlidou, M. Bone Architecture: Collagen Structure and Calcium/Phosphorus Maps. *J. Biol. Phys.* **34**, 39 (2008).
31. Dada, S., Burger, M. C., Massij, F., de Wet, H. & Collins, M. Carpal tunnel syndrome: The role of collagen gene variants. *Gene* **587**, 53–58 (2016).
32. Alakhdar, Y. *et al.* Association Between COL5a1, COL11a1, and COL11a2 Gene Variations and Rotator Cuff Tendinopathy in Young Athletes. *Clin. J. Sport Med.* **31**, (2021).
33. Alakhdar Mohmara, Y. *et al.* Influence of genetic factors in elbow tendon pathology: a case-control study. *Sci. Rep.* **10**, 1–7 (2020).
34. Hay, M. *et al.* Association of type XI collagen genes with chronic Achilles tendinopathy in independent populations from South Africa and Australia. *Br. J. Sports Med.* **47**, 569–574 (2013).
35. Lamas, J. R. *et al.* Large-scale gene expression in bone marrow mesenchymal stem cells: a putative role for COL10A1 in osteoarthritis. *Ann. Rheum. Dis.* **69**, 1880–1885 (2010).
36. Ikejawa, S. *et al.* Mutation of the Type X Collagen Gene (COL10A1) Causes Spondylometaphyseal Dysplasia. *Am. J. Hum. Genet.* **63**, 1659–1662 (1998).
37. Warman, M. L. *et al.* A type X collagen mutation causes Schmid metaphyseal chondrodysplasia. *Nat. Genet.* **5**, 79–82 (1993).
38. Kwan, K. M. *et al.* Abnormal Compartmentalization of Cartilage Matrix Components in Mice Lacking Collagen X: Implications for Function. *J. Cell Biol.* **136**, 459 (1997).
39. Lu, P., Takai, K., Weaver, V. M. & Werb, Z. Extracellular Matrix Degradation and Remodeling in Development and Disease. *Cold Spring Harb. Perspect. Biol.* **3**, (2011).
40. Xiao, Q. & Ge, G. Lysyl Oxidase, Extracellular Matrix Remodeling and Cancer Metastasis. *Cancer Microenviron.* **5**, 261 (2012).
41. Kelwick, R., Desanlis, I., Wheeler, G. N. & Edwards, D. R. The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. *Genome Biol.* **16**, 113 (2015).
42. Gingery, A. *et al.* TGF- β signaling regulates fibrotic expression and activity in carpal tunnel syndrome. *J. Orthop. Res.* **32**, 1444–1450 (2014).
43. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).

44. Hansen, T. F. *et al.* DBDS Genomic Cohort, a prospective and comprehensive resource for integrative and temporal analysis of genetic, environmental and lifestyle factors affecting health of blood donors. *BMJ Open* **9**, 28401 (2019).
45. Gudbjartsson, D. F. *et al.* Large-scale whole-genome sequencing of the Icelandic population. *Nat. Genet.* **47**, 435–444 (2015).
46. Skuladottir, A. T. *et al.* A genome-wide meta-analysis uncovers six sequence variants conferring risk of vertigo. *Commun. Biol.* 2021 **41** **4**, 1–9 (2021).
47. Skuladottir, A. T. *et al.* A meta-analysis uncovers the first sequence variant conferring risk of Bell's palsy. *Sci. Rep.* **11**, 4188 (2021).
48. Jónsson, H. *et al.* Data Descriptor: Whole genome characterization of sequence diversity of 15,220 Icelanders. *Sci. Data* **4**, 1–9 (2017).
49. Eggertsson, H. P. *et al.* GraphTyper enables population-scale genotyping using pangenome graphs. *Nat. Genet.* **49**, 1654–1660 (2017).
50. Kong, A. *et al.* Detection of sharing by descent, long-range phasing and haplotype imputation. *Nat. Genet.* **40**, 1068–1075 (2008).
51. Gudbjartsson, D. F. *et al.* Sequence variants from whole genome sequencing a large group of Icelanders. *Sci. Data* **2**, 1–11 (2015).
52. Wain, L. V. *et al.* Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): A genetic association study in UK Biobank. *Lancet Respir. Med.* **3**, 769–781 (2015).
53. Welsh, S., Peakman, T., Sheard, S. & Almond, R. Comparison of DNA quantification methodology used in the DNA extraction protocol for the UK Biobank cohort. *BMC Genomics* **18**, (2017).
54. Delaneau, O., Zagury, J. F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T. Accurate, scalable and integrative haplotype estimation. *Nat. Commun.* **10**, 1–10 (2019).
55. Loh, P. R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat. Genet.* **48**, 1443–1448 (2016).
56. Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. *J. Natl. Cancer Inst.* **22**, 719–748 (1959).
57. A, K. *et al.* Selection against variants in the genome associated with educational attainment. *Proc. Natl. Acad. Sci. U. S. A.* **114**, E727–E732 (2017).
58. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1236–1241 (2015).
59. Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int. J. Epidemiol.* **46**, 1734 (2017).
60. Saevarsdottir, S. *et al.* FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease. *Nature* **584**, 619–623 (2020).
61. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).

62. Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. *Nat. Protoc.* 7, 500–507 (2012).

Figures

Figure 1

A Manhattan plot of the CTS meta-analysis results, highlighting 50 loci. The $-\log_{10}P$ -values (y-axis) are plotted for each variant against their chromosomal position (x-axis). Variants with P -values below their weighted variant-class threshold are marked in orange. Manhattan plots for the different datasets used are shown in Supplementary Fig. 2.

Figure 2

Functional annotation and gene-set analysis. a) Variants ($N = 22$) with evidence pointing to a single effect-mediating gene in the form of protein-coding or splicing variants, variants affecting mRNA expression (top *cis*-eQTL) or plasma protein levels (pQTL), and variants ($N = 4$) with evidence of pathogenicity (CADD score ≥ 12.4 , suggested threshold for pathogenicity¹⁸). b) Gene-set enrichment analysis revealed an enrichment for genes encoding proteins that are components of the extracellular matrix. The Venn diagram divides the implicated genes into groups based on the functional role of the encoded protein in the extracellular matrix; regulation, secretion, and/or structure. Genes encoding proteins in different protein categories are colored black (collagens), gray (protease inhibitors), navy (proteoglycans), turquoise (glycoproteins), orange (proteases), and bronze (other proteins).

Figure 3

Genetic propensity for CTS in suggested severity groups. The results from the PRS analyses were meta-analyzed²⁰ (see Supplementary Figure 4 for each dataset). The OR and 95% CI adjusted for genomic inflation on x-axis, were estimated in each group, y-axis.

Figure 4

Regional plot of the *SERPINA1* locus. Variants are colored by the degree of correlation (r^2) with the lead variant, which is colored black. Moderate impact variants are represented by squares. The $-\log_{10}P$ -values on the left y-axis (two-sided logistic regression) are plotted for each variant against their chromosomal position (x-axis). The right y-axis shows calculated recombination rates based on the Icelandic data at the chromosomal location, plotted as solid black lines.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarydata.xlsx](#)
- [Supplementaryinformation.docx](#)
- [Supplementaryinformation.docx](#)